TARGET Publication Guidelines

The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) program is a community resource project, and data are made available rapidly after validation for use by other researchers.

TARGET Program Attribution in Publications and Presentations

TARGET requests that authors who use data from TARGET acknowledge the appropriate Project Team(s) in their work by referencing the TARGET dataset in accordance with the Data Use Certification posted at dbGaP. If investigators desire to collaborate with TARGET members, they should contact the PI of the disease project team.

We suggest the following language: "The results published here are in whole or part based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatments ( initiative, phs000218. The data used for this analysis are available at"

Disease dbGaP Sub-study ID
Acute Lymphoblastic Leukemia (ALL) Pilot Phase 1 phs000463
Acute Lymphoblastic Leukemia (ALL) Expansion Phase 2 phs000464
Acute Myeloid Leukemia (AML) phs000465
Cancer Model Systems (MDLS): Cell Lines and Xenografts
(including Pediatric Preclinical Testing Program––PPTP)
Clear Cell Sarcoma of the Kidney (CCSK) phs000466
Neuroblastoma (NB) phs000467
Osteosarcoma (OS) phs000468
Rhabdoid Tumor (RT) phs000470
Wilms Tumor (WT) phs000471

For questions, please contact the TARGET Publications Committee at

Researchers who plan to prepare manuscripts containing descriptions of TARGET pediatric cancer data that would be of comparable scope to an initial TARGET disease-specific comprehensive, global analysis publication, and journal editors who receive such manuscripts, are strongly encouraged to coordinate their independent reports with TARGET’s publication schedule. Specifically, comparable scope is defined as global genome-wide analysis of TARGET disease-specific data from one or more than one platform or a trans-TARGET manuscript. If you have questions, do not hesitate to contact

Last updated: April 26, 2021